Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

American Journal of Hematology

Volumn 88, Issue 11, 2013, Pages 961-966

  Nazha, Aziz ^a   Kantarjian, Hagop ^a   Ravandi, Farhad ^a   Huang, Xuelin ^a   Choi, Sangbum ^a   Garcia Manero, Guillermo ^a   Jabbour, Elias ^a   Borthakur, Gautam ^a   Kadia, Tapan ^a   Konopleva, Marina ^a   Cortes, Jorge ^a   Ferrajoli, Alessandra ^a   Kornblau, Steve ^a   Daver, Naval ^a   Pemmaraju, Naveen ^a   Andreeff, Michael ^a   Estrov, Zeev ^a   Du, Min ^a   Brandt, Mark ^a   Faderl, Stefan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLOFARABINE; CYTARABINE; IDARUBICIN; ITRACONAZOLE; LEVOFLOXACIN; VALACICLOVIR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; COMPARATIVE STUDY; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE INCREASE; DRUG FATALITY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; INDUCTION CHEMOTHERAPY; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SEIZURE; SIDE EFFECT; STOMATITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADENINE NUCLEOTIDES; ADULT; AGE FACTORS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; CONSOLIDATION CHEMOTHERAPY; CYTARABINE; DRUG ERUPTIONS; FOLLOW-UP STUDIES; HUMANS; IDARUBICIN; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; NAUSEA; PILOT PROJECTS; REMISSION INDUCTION; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84886286103     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23544     Document Type: Article

References (28)

1. Yates JW, Wallace HJ Jr, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 1973;57:485-488.
2. Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: A study by cancer and leukemia group B. Blood 1981;58:1203-1212.
3. O'Donnell MR, Abboud CN, Altman J, et al. Acute myeloid leukemia. J Natl Compr Canc Netw 2011;9:280-317.
4. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481-3485.
5. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249-1259.
6. Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: The EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009;27:5397-5403.
7. Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial. J Clin Oncol 2010;28:586-595.
8. Kolitz JE, George SL, Dodge RK, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 2004;22:4290-4301.
9. Holowiecki J, Grosicki S, Robak T, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 2004;18:989-997.
10. Ohtake S, Miyawaki S, Fujita H, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: The JALSG AML201 study. Blood 2011;117:2358-2365.
11. Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349:743-752.
12. Thomas X, Raffoux E, Renneville A, et al. Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Cancer 2010;116:1725-1732.
13. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood 2001;98:3212-3220.
14. Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B. Blood 1991;78:2520-2526.
15. Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer 2006;107:116-124.
16. Ravandi F, Cortes J, Faderl S, et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood 2010;116:5818-5823; quiz 6153.
17. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903.
18. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173-4179.
19. Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S. Clofarabine: past, present, and future. Leuk Lymph 2007;48:1922-1930.
20. Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003;21:1167-1173.
21. Faderl S, Ferrajoli A, Wierda W, et al. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 2008;113:2090-2096.
22. Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 1995;55:2847-2852.
23. Plunkett W, Liliemark JO, Estey E, Keating MJ. Saturation of ara-CTP accumulation during high-dose ara-C therapy: Pharmacologic rationale for intermediate-dose ara-C. Semin Oncol 1987;14:159-166.
24. Cooper T, Ayres M, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol 2005;55:361-368.
25. Szmigielska-Kaplon A, Ciesielska E, Szmigiero L, Robak T. Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro. Eur J Haematol 2002;68:370-375.
26. Russo D, Malagola M, de Vivo A, et al. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. Br J Haematol 2005;131:172-179.
27. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study. Blood 1996;88:2841-2851.
28. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354-365.